SavedAdd your journal

Journals / Eurasian Journal of Medical Investigation / 2021 / Cilt: 5 - Sayı: 1

Clinical Outcomes of Kaposi’s Sarcoma Treated with Systemic Chemotherapy

Melike ÖZÇELİK
Abdilkerim OYMAN
Mustafa BASAK
Mahmut Emre YILDIRIM
Pages
12–15
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The aggressive state of the disease which isineligible for local treatment can be controlled by systemic chemotherapy.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: We aimed to examine the clinical and epidemiological features of the patients diagnosed with Kaposi’ssarcoma, who were treated with systemic chemotherapy.Methods: Patients with age of 18 years or older and histopathologically confirmed Kaposi sarcoma, were included inthe study.
📊
Key Findings & Data:Demographic data, tumor histology and characteristics, Kaposi’s sarcoma subtype and treatment modalitieswere retrospectively evaluated.Results: A total of 20 patients were included in the study.
💡
Conclusion & Impact:The aggressive state of the disease which isineligible for local treatment can be controlled by systemic chemotherapy.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: We aimed to examine the clinical and epidemiological features of the patients diagnosed with Kaposi’ssarcoma, who were treated with systemic chemotherapy.Methods: Patients with age of 18 years or older and histopathologically confirmed Kaposi sarcoma, were included inthe study. Demographic data, tumor histology and characteristics, Kaposi’s sarcoma subtype and treatment modalitieswere retrospectively evaluated.Results: A total of 20 patients were included in the study. Fourteen patients (70%) were found to be related with HHV8. Five patients (25%) were HIV-positive. The lesions were located in the lower extremities in 19 patients (95%), upperextremities in 11 patients (55%), head and neck in 11 patients (55%) and trunk in 6 patients (30%). All 20 patients unresponsive to the local treatments including two patients with visceral metastases received chemotherapy. Completeremission was achieved in seven patients (35%), partial response was achieved in seven patients (35%) and stableresponse was achieved in four patients (20%) with the systemic chemotherapy.Conclusion: The success rate is high with the practice of local treatments. The aggressive state of the disease which isineligible for local treatment can be controlled by systemic chemotherapy.

🔖

Cite This Article

ÖZÇELİK, M., OYMAN, A., BASAK, M., YILDIRIM, M. E. (2022). Clinical Outcomes of Kaposi’s Sarcoma Treated with Systemic Chemotherapy. Eurasian Journal of Medical Investigation, Cilt: 5 - Sayı: 1, 12–15. https://ajindex.com/articles/508611

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Kaposi M. Idiopathisches multiples pigmentsarkom der haut. Arch Dermatol Syphilol 1872;4:742–9
  2. Di Lorenzo G. Update on classic Kaposi’s sarcoma therapy: new look at an old disease. Crit Rev Oncol Hematol 2008;68:242–9
  3. Schwartz RA, Micali G, Nasca MR, Scuderi L. Kaposi’s sarcoma: a continuing conun-drum. J Am Acad Dermatol 2008;59:179– 206
  4. Curtiss P, Strazzulla LC, Friedman-Kien AE. An Update on Kaposi’s Sarcoma: Epidemiology, Pathogenesis and Treatment. Dermatol Ther (Heidelb) 2016;6:465–70
  5. Schneider JW, Dittmer DP. Diagnosis and treatment of Kaposi’s sarcoma. Am J Clin Dermatol2017;18:529–39
  6. Stratigos JD, Potouridou I, Katoulis AC, Hatziolou E, Christofidou E, Stratigos A, et al. Classic Kaposi's sarcoma in Greece: a clinicoepidemiological profile. Int J Dermatol 1997;36:735–40
  7. Lospalluti M, Mastrolonardo M, Loconsole F, Conte A, Rantuccio F. Classical Kaposi's sarcoma: a survey of 163 cases observed in Bari, south Italy. Dermatology 1995;191:104–8
  8. Su Ö, Onsun N, Arda H, Ümmetoğlu Ö, Pakdemir A. Clinical features, presence of human herpesvirus-8 and treatment results in classic Kaposi’s sarcoma. Turkderm–Arch Turk Dermatol Venerol 2008;42:122–6
  9. Oysul K, Beyzadeoglu M, Surenkok S, Ozyigit G. A dose-response analysis for classical Kaposi’s sarcoma management by radiotherapy. Saudi Med J 2008;29:837–40
  10. Dogan M, Dogan L, Ozdemir F, Ozdemir NY, Coskun HS, Arslan UY, et al. Fifty-one Kaposi sarcoma patients. Clin Transl Oncol 2010;12:629–33
  11. Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994;266:1865–9
  12. Dukers NH, Rezza G. Human herpesvirus 8 epidemiology: what we do and do not know. AIDS 2003;17:1717–30
  13. Whitby D, Boshoff C, Weiss RA, Luppi M, Barozzi P, Torelli G, et al. Human herpesvirus 8 seroprevalence in blood donors and lymphoma patients from different regions of Italy. J Natl Cancer Inst 1998;90:395–97
  14. Demirel BG, Koca R, Tekin NS, Kandemir NO, Gün BD, Köktürk F, et al. Classic Kaposi’s sarcoma: The clinical, demographic and teratment characteristics of seventy-four patients. Turkderm - Arch Turk Dermatol Venerology 2016;50:136–40
  15. Laresche C, Fournier E, Dupond AS, Woronoff AS, DrobacheffThiebaut C, Humbert P, et al. Kaposi's sarcoma: a populationbased cancer registry descriptive study of 57 consecutive cases diagnosed between 1977 and 2009. Int J Dermatol 2014;53:e549–54. 16